Results 171 to 180 of about 31,440 (256)

Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Ahuja A, Prasad S, Manoharan S, Sen A, Rana R, Mody M, Paras F, Archita A, Shaik S, Mehta K, Manoj R, Mishra P, Mehta S, Kapoor P.   +13 more
europepmc   +1 more source

Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland.
Atte Vaden, Mari Lahelma, Lalli Nurmi, Eija Heikkilä, Hannu Vessari, Hanne Luoto, Tero Saukkonen, Leo Niskanen   +7 more
wiley   +1 more source

A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists. [PDF]

J Clin Med
Virk A, Allison K.
europepmc   +1 more source

Diabetes and menopause: A critical yet neglected intersection

Diabetic Medicine, EarlyView.
Isabell Haage, David Studer, Petra Stute, Lia Bally   +3 more
wiley   +1 more source

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant‐Level Exploratory Analysis of the Randomised CONFIDENCE Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). Materials and Methods Adults with type 2 diabetes and a urinary albumin‐to‐creatinine ratio (UACR) of 100 − < 5000 mg/g, estimated glomerular ...
Janet B. McGill, Jennifer B. Green, Hiddo J. L. Heerspink, Johannes F. E. Mann, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Masaomi Nangaku, Meike Brinker, Charlie Scott, Katja Rohwedder, Li Li, Na Li, Margarida Seco, Rajiv Agarwal   +15 more
wiley   +1 more source

GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity. [PDF]

Curr Nutr Rep
Simsek H, Ucar A.
europepmc   +1 more source

Pre‐Exercise Galactose or Lactose Reduces Glycaemic Excursions During Exercise in Adults With Type 1 Diabetes: A Randomised, Double‐Blind, Crossover Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To test whether pre‐exercise galactose and lactose reduce glycaemic excursions during exercise compared with dextrose while maintaining protection against hypoglycaemia compared with placebo in adults with Type 1 diabetes Methods In a randomised, double‐blind, 4‐condition crossover trial, 14 adults with Type 1 diabetes completed four 60 ...
Karoline R. Schmidt, Rakel F. Johansen, Simon B. Riis, Mads S. Larsen, Henrik Støvring, Gareth A. Wallis, David Rowlands, Lars C. Gormsen, Esben Søndergaard   +8 more
wiley   +1 more source

GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives. [PDF]

Pharmaceutics
Andrzejczak K, Kucharczyk E, Korgiel M, Drozdowska J, Maj J, Ponikowska M.   +5 more
europepmc   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular‐kidney‐metabolic (CKM) syndrome has developed into a global public health crisis. Although integrated care is increasingly used to treat patients with CKM, current health economic models fail to capture the value of considering the CKM syndrome as a unified condition.
Volker Foos, Jieling Chen, Phil McEwan, Marc Evans, Pardeep S. Jhund, Paul R. Kalra, Hongtu Zhu, David C. Wheeler, Geraint Roberts, Martin R. Cowie, Andrew H. Briggs   +10 more
wiley   +1 more source